BRITISH JOURNAL OF DERMATOLOGY英国皮肤病学杂志
BRITISH JOURNAL OF DERMATOLOGY(英文缩写 BRIT J DERMATOL),ISSN 0007-0963,eISSN 1365-2133,中文译名:英国皮肤病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 11.113 | Q1 |
| 2022 | 10.300 | Q1 |
| 2023 | 11.000 | Q1 |
| 2024 | 9.600 | Q1 |
| 2025 | 8.200 | Q1 |
BRITISH JOURNAL OF DERMATOLOGY 最新收录文献
-
5. Generalized Cutaneous Hyperpigmentation and Lentigines due to KIT Variant.
PMID:日期:2026-09-22该文献暂无摘要。
-
7. Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.
PMID:日期:2026-09-21Conventional response endpoints do not adequately capture durable clinical benefit in mycosis fungoides (MF) and Sézary syndrome (SS). Overall response lasting ≥ 4 months (ORR4) has been proposed as a clinically meaningful endpoint in clinical trials, but its prognostic value in real-world mogamulizumab-treated patients remains unknown. To evaluate the effectiveness and safety of mogamulizumab in routine clinical practice and investigate the prognostic relevance of ORR4 in patients with MF/SS. FIL-MOGA was a nationwide, multicenter, retrospective study including 98 patients with MF/SS treated with mogamulizumab between January 2021 and December 2023 across 18 centers of the Italian Lymphoma Foundation (FIL). The primary endpoint was ORR4. Survival outcomes were assessed using Kaplan-Meier estimates, 4-month landmark analyses, and Cox proportional hazards models treating ORR4 as a time-varying covariate (TVC). After a median follow-up of 35 months, ORR4 was achieved in 44 of 93 (47.3%) evaluable patients. Best overall response increased from 29.4% at 1 month to 38.0% at 4 months and 58.1% during follow-up. ORR4 varied significantly according to baseline disease stage (p=0.022), ranging from 10.0% in stage IIB to 70.8% in stage IVA1 disease. In landmark analyses, ORR4 was associated with improved 24-month OS (76% vs 60%; p=0.006), PFS (58% vs 35%; p=0.001), and TTNT (76% vs 47%; p=0.002). These findings were confirmed in time-dependent analyses (OS HR 2.53, p=0.008; PFS HR 2.70, p=0.001; TTNT HR 3.04, p=0.003). In multivariable models, lack of ORR4 remained independently associated with worse OS (HR 3.18, p=0.002), PFS (HR 2.67, p=0.002), and earlier initiation of subsequent systemic therapy (HR 4.27, p=0.001). Skin adverse events were associated with higher ORR4 rates (70% vs 40%, p=0.017) but not independently with survival outcomes. Thirteen patients (13%) underwent allogeneic hematopoietic stem cell transplantation after mogamulizumab. This large real-world study confirms the effectiveness of mogamulizumab and identifies ORR4 as a robust on-treatment prognostic marker independently associated with OS, PFS and TTNT. These findings support the incorporation of ORR4 as a clinically meaningful endpoint in real-world studies and routine management of MF/SS.
-
9. Incidence, prevalence, and life expectancy of patients with generalised pustular psoriasis in England: a population-based cohort study exploring ethnic and sex variations.
PMID:日期:2026-09-21Generalised pustular psoriasis (GPP) is a rare, severe inflammatory skin disease associated with significant morbidity and increased mortality. Population-based data on the epidemiology of GPP examining ethnic and sex differences, and life-expectancy, remain scarce. To examine the epidemiology of GPP in England over a 15-year period (2008-2022), all-cause and cause-specific mortality risk associated with GPP, and life expectancy including years of life lost associated with age at diagnosis. A population-based cohort study using the Clinical Practice Research Datalink linked with hospital, mortality, deprivation, and ethnicity records. Patients with a diagnosis of GPP from primary care or hospital records were identified. Annual prevalence and incidence rates were calculated. Individuals with incident GPP were matched with up to 10 comparators without GPP. Flexible parametric survival models estimated adjusted hazard ratios (aHRs) for the association between GPP and mortality. Abridged life tables were used to estimate years of life lost. Among 25.8 million people, 991 with GPP were identified (63% female; 86% White, 10% Asian, 3% Black/Mixed/Other). GPP prevalence increased from 20.9 per million in 2008 to 32.5 per million in 2022, with higher rates in females, the Asian population, and older age groups. Incidence remained stable until 2016, followed by an upward trend reaching 4.9 per million person-years. Mean age (SD) at onset was 51.4 (21.2) years, occurring earlier in Asian people than in White people. All-cause mortality risk was over three times higher for patients with GPP compared with people without GPP (aHR 3.19; 95% CI 2.58-3.91). Death rates were elevated with GPP for neoplasms, respiratory, digestive, and circulatory diseases, and particularly sepsis (aHR 9.76 [4.92-19.35]). A younger age at diagnosis of GPP was associated with the greatest reduction in life expectancy. Over the past 15 years, the prevalence of GPP in England increased by more than 50%, with notable differences by sex and ethnicity. GPP was associated with elevated risks of all-cause and cause-specific mortality and reductions in life expectancy. These findings highlight the clinical burden of GPP and the need for appropriate and targeted strategies to reduce preventable morbidity and mortality.
-
10. Determinants of real-world sunscreen effectiveness: from ultraviolet radiation photobiology to human behaviour.
PMID:日期:2026-09-21Sunscreen is often presented as a straightforward intervention for reducing sun-induced skin damage. In practice, however, its effectiveness is determined by a broad network of interacting factors rather than labelled Sun Protection Factor (SPF) alone. Real-world protection depends not only on filter chemistry and test performance, but also on wavelength coverage, formulation, durability, regulatory standards, user behaviour and public understanding. At the same time, sunscreen has become an increasingly contested topic, shaped by debates regarding systemic absorption, environmental impact, misinformation and the limitations of uniform public-health messaging. This review examines the determinants of sunscreen effectiveness in the real world. First, the photobiological basis of photoprotection is considered, including the differing contributions of UVB, UVA, and, in selected contexts, visible light to skin damage. Second, the ways in which sunscreen efficacy is measured and regulated are reviewed, with particular attention to the limitations of SPF as a sole marker of protection. Third, current evidence relating to human and environmental implications of sunscreen use is assessed. Finally, behavioural, social and communicative factors that influence real-world use are explored, together with emerging personalised and technological approaches to photoprotection. Overall, the evidence suggests that sunscreen effectiveness is best understood not as a fixed property of the product alone, but as the outcome of an interaction between photobiology, formulation science, regulation and human behaviour. This broader framework helps explain why scientifically efficacious products may deliver suboptimal protection in practice, and why future improvements in photoprotection will depend not only on innovation in formulations, but also on clearer, more risk-stratified guidance that supports consistent use in everyday life.